Genexine (A095700) Stock Overview
Operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
A095700 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Genexine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,790.00 |
| 52 Week High | ₩7,490.00 |
| 52 Week Low | ₩2,140.00 |
| Beta | 0 |
| 1 Month Change | 6.49% |
| 3 Month Change | -8.52% |
| 1 Year Change | -48.62% |
| 3 Year Change | -71.68% |
| 5 Year Change | -95.18% |
| Change since IPO | -73.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| A095700 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -8.7% | -4.6% | 3.1% |
| 1Y | -48.6% | -16.1% | 92.1% |
Return vs Industry: A095700 underperformed the KR Biotechs industry which returned -16.1% over the past year.
Return vs Market: A095700 underperformed the KR Market which returned 92.1% over the past year.
Price Volatility
| A095700 volatility | |
|---|---|
| A095700 Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in KR Market | 16.4% |
| 10% least volatile stocks in KR Market | 4.4% |
Stable Share Price: A095700's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A095700's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | n/a | www.genexine.com |
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes.
Genexine, Inc. Fundamentals Summary
| A095700 fundamental statistics | |
|---|---|
| Market cap | ₩128.93b |
| Earnings (TTM) | -₩54.53b |
| Revenue (TTM) | ₩5.81b |
Is A095700 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A095700 income statement (TTM) | |
|---|---|
| Revenue | ₩5.81b |
| Cost of Revenue | ₩6.00b |
| Gross Profit | -₩196.75m |
| Other Expenses | ₩54.33b |
| Earnings | -₩54.53b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A095700 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 08:28 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genexine, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ka-hye Hong | Daishin Securities Co. Ltd. |
| Hyerin Lee | DAOL Investment & Securities Co., Ltd. |
| Ha Young Kang | DAOL Investment & Securities Co., Ltd. |